Odyssey Therapeutics, a Boston, MA-based biotechnology company, raised $168M in Series B funding.
The round was led by General Catalyst, with participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures.
The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases.
Gary D. Glick, Ph.D., Founder and Chief Executive Officer, Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing immunomodulators and oncology medicines. Its immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics. In addition, Odyssey is building a discovery engine that integrates artificial intelligence and machine learning for molecular design; a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products; and a functional genomics platform for novel target discovery.
FinSMEs
13/10/2022